WeLeader Biomedical Co., Ltd. (TPEX:7713)
Taiwan · Delayed Price · Currency is TWD 68.30
-1.10 (-1.59%)
At close: Mar 27, 2026
WeLeader Biomedical Revenue
In the year 2025, WeLeader Biomedical had annual revenue of 1.11B TWD with 11.92% growth. WeLeader Biomedical had revenue of 295.19M in the quarter ending December 31, 2025, with 19.07% growth.
Revenue
1.11B
Revenue Growth
+11.92%
P/S Ratio
2.80
Revenue / Employee
n/a
Employees
n/a
Market Cap
3.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.11B | 118.18M | 11.92% |
| Dec 31, 2024 | 991.13M | 50.43M | 5.36% |
| Dec 31, 2023 | 940.70M | -95.02M | -9.17% |
| Dec 31, 2022 | 1.04B | 194.58M | 23.13% |
| Dec 31, 2021 | 841.14M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Wellell | 2.40B |
| InnoCare Optoelectronics | 2.29B |
| OK Biotech | 1.56B |
| Dynamic Medical Technologies | 1.39B |
| A Plus Biotechnology | 835.89M |
| Diamond Biotechnology | 698.11M |
| Delta Asia International | 694.15M |
| Medimaging Integrated Solution | 661.39M |